SynthesisRetina (Philadelphia, Pa.)2026
SILICONE OIL MIGRATION DURING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS: A Review of Clinical Evidence and Factors Related to Transmission.
Synthesis in Retina (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the incidence, mechanisms, and clinical implications of silicone oil droplet transmission during intravitreal anti-vascular endothelial growth factor injections and to review strategies to mitigate contamination risks.
methodsA systematic review of observational and review studies from PubMed and MEDLINE was conducted, focusing on incidence, contributing factors, and clinical outcomes of silicone oil contamination during IVIs. Specific attention was given to syringe design, storage conditions, variations among anti-vascular endothelial growth factor agents, and injection techniques.
resultsThe review found that prevalence is high in chronically injected eyes, although per-injection rates are low, often clustering because of syringe batches or techniques. Contributing factors include freeze-thaw cycles, mechanical agitation, spray-siliconized low dead space syringes, and improper plunger handling, which can lead to asymptomatic droplets or symptomatic floaters. No severe complications such as endophthalmitis were reported. Hypotheses link silicone oil to ocular hypertension or inflammation via trabecular obstruction or immunogenic responses, but the reviewed studies show no direct evidence. Mitigation involves the use of silicone-free/prefilled syringes, strict storage, gentle handling, and refined techniques such as priming and smooth plunger depression.
conclusionSilicone oil contamination during IVIs can be minimized through careful optimization of syringe design, handling practices, and injection techniques. Embracing silicone-free or low-silicone syringe systems, alongside meticulous procedural protocols, offers the potential to enhance the safety and clinical outcomes of intravitreal anti-vascular endothelial growth factor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.